Table 2.

Cumulative incidence (n, %) of adverse events in patients treated with placebo and nangibotide in the ESSENTIAL trial between initiation of study drug and study day 28.

	Placebo (n = 100)	Nangibotide (n = 119)
Total AE n	587	659
Patients with at least 1 AE n (%)	90 (90.0)	104 (87.4)
Total AE related to study drug n	5	4
Patients with at least 1 AE related to study drug n (%)	4 (4.0)	4 (3.4)
Total AE leading to death n	27	19
Total SAE n	60	63
Patients with at least 1 SAE n (%)	43 (43.0)	33 (27.7)
Total SAE related to study drug n	3	1
Patients with at least 1 SAE related to study drug n (%)	3 (3.0)	1 (0.8)